Every 424B that OnKure Therapeutics (OKUR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
Okur is amending its existing shelf registration to continue an at-the-market program for the offer and sale of up to $100,000,000 of Class A common stock through or to Leerink Partners under a Sales Agreement. The company states it is no longer subject to General Instruction I.B.6 of Form S-3, which had limited the amount it could sell under this registration.
As of August 4, 2026, no shares have been offered or sold under this program. The aggregate market value of Class A common stock held by non-affiliates was $167.3 million as of August 3, 2026, based on 36,368,892 non-affiliate shares at $4.60 per share; this is a baseline figure, not the amount being offered. Leerink Partners may receive up to 3.0% of gross proceeds as sales compensation. Okur is characterized as an “emerging growth company” and “smaller reporting company,” and investors are directed to the referenced risk factor sections before investing.
OnKure Therapeutics, Inc. is registering 1,507,685 shares of its Class A common stock for resale by investors who bought these shares in an October 4, 2024 private PIPE financing. This is a secondary offering only, so all sale proceeds will go to the selling securityholders, while OnKure will cover registration and listing expenses.
The shares may be sold from time to time by the selling securityholders using various methods, including market and privately negotiated transactions, at market or negotiated prices. OnKure’s Class A common stock trades on Nasdaq under the symbol “OKUR,” and the last reported sale price on November 20, 2025 was $2.62.
As context, there were 12,861,672 shares of Class A common stock and 686,527 shares of non-voting Class B common stock outstanding as of September 30, 2025. Class B shares are convertible into Class A shares subject to a beneficial ownership cap that initially limits holders to 9.9% of outstanding Class A shares.
OnKure Therapeutics, Inc. filed a prospectus supplement registering the resale of 2,938,005 shares of Class A Common Stock previously issued in a PIPE financing. The supplement updates the prospectus dated March 21, 2025 and must be read together with it. The prospectus also covers any additional securities issuable due to stock splits, stock dividends, or similar events.
The company attached its latest Quarterly Report on Form 10-Q and a Current Report on Form 8-K. As of November 5, 2025, shares outstanding were 12,861,672 for Class A common stock and 686,527 for Class B common stock. For the quarter ended September 30, 2025, cash and cash equivalents were $70.3 million, and net loss was $14.7 million, reflecting continued R&D investment as OKI-219 advances in a first-in-human Phase 1a/1b trial. Management states cash resources are sufficient to fund the current operating plan for at least the next 12 months from the financial statement issuance date.